Company announces $30 million Series A financing and founding leadership team with expertise in pulmonary drug innovation and track record ...

Idiopathic pulmonary fibrosis slowly turns the lungs stiff and scarred, but researchers may have found why the damage keeps ...

The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring ...

Iron metabolism imbalance and ferroptosis are central to PF pathogenesis, offering new therapeutic targets. Ferroptosis links oxidative stress, iron overload, and fibrotic remodeling, affecting key ...

Two phase 3, randomized trials of inhaled treprostinil for idiopathic pulmonary fibrosis (IPF) were conducted on the basis of preclinical and clinical evidence of an antifibrotic mechanism.

Panelists discuss how idiopathic pulmonary fibrosis (IPF), a progressive and often fatal interstitial lung disease, presents significant clinical challenges due to its variable trajectory, limited ...

Treprostinil currently carries indications for improving exercise ability in pulmonary arterial hypertension and pulmonary ...

Cell-cell interactions via proteins and ligand-receptor interactions contribute to PF pathogenesis. Single-cell RNA genome sequencing technique and bio-informatics oriented approaches combined with ...

ORJ-001 achieved therapeutic exposure and was well tolerated in Phase 1 study, supporting company’s plans to initiate Phase 2 clinical trial in IPF patients ...